Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors

被引:0
作者
Shuhang Wang [1 ]
Yongping Song [2 ]
Feifei Yan [1 ]
Delong Liu [2 ]
机构
[1] The Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital
[2] Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
关键词
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
The tyrosine kinase inhibitors(TKI) of the epidermal growth factor receptor(EGFR) are becoming the first line of therapy for advanced non-small cell lung cancer(NSCLC).Acquired mutations in EGFR account for one of the major mechanisms of resistance to the TKIs.Three generations of EGFRTKIs have been used in clinical applications.AZD9291(osimertinib;Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positive advanced NSCLC patients.However,resistance to AZD9291 arises after 9-13 months of therapy.The mechanisms of resistance to third-generation inhibitors reported to date include the EGFR C797 S mutation,EGFR L718 Q mutation,and amplifications of HER-2,MET,or ERBB2.To overcome the acquired resistance to AZD9291,EAI045 was discovered and recently reported to be an allosteric EGFR inhibitor that overcomes T790M-and C797S-mediated resistance.This review summarizes recent investigations on the mechanisms of resistance to the EGFR TKIs,as well as the latest development of EAI045 as a fourth-generation EGFR inhibitor.
引用
收藏
页码:383 / 388
页数:6
相关论文
共 50 条
[31]   Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy [J].
Cheng, Weiyan ;
Zhou, Jianhua ;
Tian, Xin ;
Zhang, Xiaojian .
CURRENT MEDICINAL CHEMISTRY, 2016, 23 (29) :3343-3359
[32]   Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management (vol 19, pg 499, 2022) [J].
Cooper, Alissa J. ;
Sequist, Lecia V. ;
Lin, Jessica J. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (11) :744-744
[33]   Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors [J].
Du, Xiaojing ;
Yang, Biwei ;
An, Quanlin ;
Assaraf, Yehuda G. ;
Cao, Xin ;
Xia, Jinglin .
INNOVATION, 2021, 2 (02)
[34]   Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors [J].
Westover, D. ;
Zugazagoitia, J. ;
Cho, B. C. ;
Lovly, C. M. ;
Paz-Ares, L. .
ANNALS OF ONCOLOGY, 2018, 29 :I10-I19
[35]   Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients [J].
Yang, Zhe ;
Yang, Nong ;
Ou, Qiuxiang ;
Xiang, Yi ;
Jiang, Tao ;
Wu, Xue ;
Bao, Hua ;
Tong, Xiaoling ;
Wang, Xiaonan ;
Shao, Yang W. ;
Liu, Yunpeng ;
Wang, Yan ;
Zhou, Caicun .
CLINICAL CANCER RESEARCH, 2018, 24 (13) :3097-3107
[36]   Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors [J].
Xu, H. ;
Shu, Y. ;
Jian, H. ;
Shen, J. ;
Xiang, J. ;
Li, H. ;
Li, B. ;
Zhang, T. ;
Zhang, L. ;
Mao, X. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S562-S563
[37]   Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update [J].
Ahsan, Aarif .
LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 :137-153
[38]   MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma [J].
Yiming, Reheman ;
Takeuchi, Yasuto ;
Nishimura, Tatsunori ;
Li, Mengjiao ;
Wang, Yuming ;
Meguro-Horike, Makiko ;
Kohno, Takashi ;
Horike, Shin-ichi ;
Nakata, Asuka ;
Gotoh, Noriko .
CANCER SCIENCE, 2021, 112 (09) :3810-3821
[39]   MOLECULAR MECHANISMS OF ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS IN GBM [J].
Wykosky, Jill ;
Cavenee, Webster ;
Furnari, Frank .
NEURO-ONCOLOGY, 2011, 13 :16-16
[40]   Lazertinib: breaking the mold of third-generation EGFR inhibitors [J].
Patel, Kishan B. ;
Heppner, David E. .
RSC MEDICINAL CHEMISTRY, 2025, 16 (03) :1049-1066